I. Mitrica

发表

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

M. Zauderer, J. Schellens, D. Fennell, 2019, Investigational New Drugs.

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study

Jae-Weon Kim, Ji-Hong Liu, Byoung-Gie Kim, 2015, International Journal of Gynecologic Cancer.

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Jae-Weon Kim, B. Monk, I. Vergote, 2015, Gynecologic oncology.

Protein-coding genes as molecular markers for ecologically distinct populations: the case of two Bacillus species.

F. Cohan, L. K. Nakamura, I. Mitrica, 2000, International journal of systematic and evolutionary microbiology.

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.

P. Paik, E. Felip, D. Morgensztern, 2019, Lung cancer.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

K. King, M. Nelson, Chun-Fang Xu, 2015, Clinical Cancer Research.

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

I. Vergote, I. Ray-Coquard, P. Harter, 2012, British Journal of Cancer.

Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.

B. Monk, Chun-Fang Xu, T. Johnson, 2014 .

Pazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, Fallopian tube, or primary peritoneal carcinoma.

M. Yen, Byoung-Gie Kim, Lihui Wei, 2013 .

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

S. Gadgeel, D. Morgensztern, H. Kindler, 2019, Investigational New Drugs.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

K. King, M. Nelson, Chun-Fang Xu, 2015, Clinical Cancer Research.